Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Assets (2020 - 2026)

Cytek Biosciences filings provide 6 years of Assets readings, the most recent being $461.5 million for Q4 2025.

  • On a quarterly basis, Assets fell 7.6% to $461.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $461.5 million, a 7.6% decrease, with the full-year FY2025 number at $461.5 million, down 7.6% from a year prior.
  • Assets hit $461.5 million in Q4 2025 for Cytek Biosciences, down from $494.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $525.1 million in Q2 2023 to a low of $230.3 million in Q2 2021.
  • Median Assets over the past 5 years was $492.8 million (2022), compared with a mean of $479.4 million.
  • Biggest five-year swings in Assets: soared 114.01% in 2022 and later dropped 7.87% in 2024.
  • Cytek Biosciences' Assets stood at $463.3 million in 2021, then rose by 12.12% to $519.5 million in 2022, then fell by 4.82% to $494.5 million in 2023, then increased by 1.02% to $499.5 million in 2024, then dropped by 7.6% to $461.5 million in 2025.
  • The last three reported values for Assets were $461.5 million (Q4 2025), $494.9 million (Q3 2025), and $493.3 million (Q2 2025) per Business Quant data.